Key Highlights
•
A new study confirms that the youngest infants in low- and middle-income countries face the greatest risk of severe illness from respiratory syncytial virus (RSV). This finding reinforces the critical need to prioritize immunization for this vulnerable group to prevent the most serious outcomes.
Source →
•
A European study of patients with a specific type of lung disease linked to autoimmune antibodies found that a drug called rituximab was associated with improved lung function after one year. This suggests that targeted immunosuppressive therapy could help preserve breathing capacity in these complex conditions.
Source →
•
A study in 22 African countries found that about half of hospitalized adults with respiratory failure were not receiving oxygen therapy, despite it being a World Health Organization essential medicine. This highlights a major gap in basic, life-saving care in resource-limited settings.
Source →
•
A clinical trial shows that a modified dose of the COVID-19 antiviral nirmatrelvir/ritonavir is safe and maintains effective drug levels in patients with severe kidney impairment, including those on dialysis. This provides a much-needed treatment option for a high-risk group that was previously excluded from standard dosing.
Source →
•
Researchers report a case of a rare fungal skin infection caused by Paraconiothyrium cyclothyrioides in a lung transplant patient in the United States. This case alerts clinicians to consider unusual fungal pathogens in immunocompromised patients, who are at higher risk for severe infections.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
